Share Repurchase Program Declared by Haleon (LON:HLN) Board of Directors

Haleon (LON:HLN) announced that its Board of Directors has authorized a share repurchase program on Thursday, October 29th, RTT News reports. The company plans to repurchase £500 million in shares. This repurchase authorization authorizes the company to buy up to 1.8% of its stock through open market purchases. Share repurchase programs are often an indication that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

HLN has been the subject of a number of analyst reports. Royal Bank Of Canada boosted their price target on Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft upgraded Haleon to a “hold” rating and decreased their price target for the stock from GBX 320 to GBX 310 in a research note on Friday. Jefferies Financial Group reissued a “buy” rating and set a GBX 400 price objective on shares of Haleon in a report on Friday. Finally, Berenberg Bank raised their price objective on Haleon from GBX 512 to GBX 514 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of GBX 385.80.

Haleon Price Performance

Shares of Haleon stock opened at GBX 319.90 on Friday. The stock has a market capitalization of £28.14 billion, a price-to-earnings ratio of 17.67, a PEG ratio of 1.49 and a beta of 0.24. Haleon has a 1-year low of GBX 310.50 and a 1-year high of GBX 433.60. The company has a current ratio of 0.69, a quick ratio of 0.93 and a debt-to-equity ratio of 50.38. The firm has a fifty day simple moving average of GBX 352.97 and a 200-day simple moving average of GBX 360.40.

Haleon (LON:HLN) last posted its earnings results on Thursday, July 30th. The company reported GBX 8.60 earnings per share for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. On average, sell-side analysts expect that Haleon will post 19.50 earnings per share for the current year.

Key Stories Impacting Haleon

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon approved a £500 million share repurchase program, equivalent to as much as 1.8% of outstanding shares. The buyback could support earnings per share and signals that management views the shares as undervalued. Haleon Q3 Revenue Rises; Trims Annual Revenue Growth Outlook; Launches £500 Mln Share Buyback
• Positive Sentiment: Jefferies reaffirmed its buy rating and set a GBX 400 price target, implying substantial upside from recent trading levels and providing some support for the stock. Jefferies reaffirms Haleon buy rating
• Neutral Sentiment: Deutsche Bank upgraded Haleon to hold but reduced its price target to GBX 310 from GBX 320. The change reflects a more balanced view rather than a strongly bullish signal. Deutsche Bank Haleon rating update
• Neutral Sentiment: Institutional positioning was mixed, with some major investors adding Haleon shares while others reduced holdings. These moves may influence sentiment but do not establish a clear near-term direction.
• Negative Sentiment: Haleon reported third-quarter organic revenue growth of 2.6%, below expectations, and cut its 2026 organic revenue growth outlook to about 2.5% from a previous 3%–5% range. Weak cough, cold and flu demand in North America, disruption to Centrum products in China, and a planned Brazil go-to-market change contributed to the downgrade. Haleon drops after Q3 sales miss and lower 2026 growth outlook

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.